![](https://i1.wp.com/cdn.sanity.io/images/0vv8moc6/onclive/f748ae3b918a5155bb0a8fe62b1ad5f6e004f227-200x200.jpg/morris-small-thumb.jpg?fit=crop&auto=format&w=1200&resize=1200,0&ssl=1)
Presence of ctDNA Does Not Predict Benefit of Adjuvant Chemotherapy in Stage II Colon Cancer
![](https://cdn.sanity.io/images/0vv8moc6/onclive/56cb9153ca9707c44b48afcc53f2f9200fc7f11b-200x200.jpg/kasi-small-thumb.jpg?fit=crop&auto=format)
ctDNA Is Predictive of DFS, Offers Prognostic Tool in CRC
![](https://cdn.sanity.io/images/0vv8moc6/onclive/25a13f425009822d16829ffaf3e57064ff14c326-200x200.jpg/Thierry%20Andre%2C%20MD%20tn2.jpg?fit=crop&auto=format)
Frontline Nivolumab/Ipilimumab Provides Superior PFS Benefit Over Chemo in MSI-H/dMMR mCRC
![](https://cdn.sanity.io/images/0vv8moc6/onclive/f63dca7f336ea4705fc4511f75dcb75d2e206594-1122x618.png/Screenshot%202024-01-20%20at%2010.12.34%20AM.png?fit=crop&auto=format)
Dr Li on the Use of ADG126 With Pembrolizumab in MSS CRC